Contraception

On Friday, the Supreme Court voted to keep mifepristone (Mifeprex; Danco Laboratories) on the market, maintaining its availability for women seeking an abortion.

Kate White, MD, MPH, and Harold Bays, MD, discuss their hopes for the future of contraception options, affordability, and clinical trials evaluating their efficacy.

Drs Kate White and Harold Bays share their approach to initiating conversations with patients on contraception options and suggest which practitioners might be best suited to these conversations.

In a recent review, increased requests for telemedicine abortion and decreased in-person visits to abortion clinics were observed.

In a recent study, knowledge and consideration of self-managed abortion was common for patients before accessing in-clinic care.

The Supreme Court will make a decision on whether restrictions on mifepristone (Mifeprex; Danco Laboratories) should pass by Friday night.

In a recent study, the contraception failure rate for patients taking topiramate and oral contraceptives was similar to patients taking other maintenance therapies and oral contraceptives.

Kate White, MD, MPH, reviews the current contraceptive landscape and highlights the benefits of progestin-only contraception options, especially in women with higher BMIs or those concerned about missed pill windows.

An expert in cardiology reviews the current contraception selection guidelines in women with higher BMIs and comments on the cardiovascular risk associated with hormonal contraceptive methods.

In a recent study, the mean number of barriers to reproductive health care experienced by patients increased from 1.09 in 2017 to 1.29 in 2021.

A recent model indicates anovulation can be achieved through lower estrogen and progesterone levels in contraceptives than what are currently used.

A new abortion ban is set to hit the southern states, this time in Florida, with Florida Governor Robert Desantis signing a 6-week abortion ban into law. Florida is now 1 of 12 US states with approved bans on abortions after 6 weeks.

Drs Kate White and Harold Bays share their insights on hormonal contraceptive options and highlight the potential increase in venous thrombosis events in patients with high BMI.

Kate White, MD, MPH, and Harold Bays, MD, provide their thoughts on the importance of a patient-centered approach when selecting a contraceptive option in patients of child-bearing age.

In a recent study, the risk of developing breast cancer was greater in women with current or recent use of progestogen-only contraceptives.

At the 44th National Association of Pediatric Nurse Practitioners Conference, guidelines for prescribing oral contraceptives were discussed.

Contemporary OB/GYN® will continue to update this story as new information becomes available.

A recent study highlights barriers to pregnancy prevention for women without permanent housing.

Despite the popularity of birth control pills and their decades of safe use and research people still face barriers to birth control pills, said senior author Sarah Baum.

A look at contraceptive methods and how they are poised to affect women’s health.

A literature review published in the journal Contraception finds progestin-only pills (POP) may be more effective than expected.

For medication abortion, a single dose of letrozole 30 mg prior to misoprostol 800 mcg buccally is not effective, according to a recently published pilot study.

In this interview, Michael Krychman, MD, a community-based gynecologist in Newport Beach, California, takes a look at 2022 advances within the contraceptive space, as well as looks toward the future.

Community pharmacists need more support and resources to provide quality contraceptive counseling and care, according to a study published in BMJ Sexual and Reproductive Health.

Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD, according to a study in Contraception.